{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:11:35Z","timestamp":1794363095654,"version":"4.9.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872201"],"award-info":[{"award-number":["81872201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>End-stage nasopharyngeal carcinoma (NPC) has unsatisfactory survival. The limited benefit of chemotherapy and the scarcity of targeted drugs are major challenges in NPC. New approaches to treat late-stage NPC are urgently required. In this study, we explored whether the dual PI3K\/mTOR inhibitor, PQR309, exerted a favorable antineoplastic effect and sensitized the response to gemcitabine in NPC. We observed that PI3K expression was positive and elevated in 14 NPC cell lines compared with that in normal nasopharygeal cell lines. Patients with NPC with higher PI3K levels displayed poorer prognosis. We subsequently showed that PQR309 alone effectively decreased the viability, invasiveness, and migratory capability of NPC cells and neoplasm development in mice xenograft models, and dose-dependently induced apoptosis. More importantly, PQR309 remarkably strengthened the anti-NPC function of gemcitabine both in vivo and in vitro. Mechanistically, PQR309 sensitized NPC to gemcitabine by increasing caspase pathway-dependent apoptosis, blocking GSK-3\u03b2 and STAT3\/HSP60 signaling, and ablating epithelial-mesenchyme transition. Thus, targeting PI3K\/mTOR using PQR309 might represent a treatment option to promote the response to gemcitabine in NPC, and provides a theoretical foundation for the study of targeted drugs combined with chemotherapy for NPC.<\/jats:p>","DOI":"10.1038\/s41419-024-06615-8","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T10:01:47Z","timestamp":1711792907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PQR309, a dual PI3K\/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3\u03b2 and STAT3\/HSP60 signaling pathways to treat nasopharyngeal carcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8020-3603","authenticated-orcid":false,"given":"Jiaxin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiteng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhuo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-3888","authenticated-orcid":false,"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,30]]},"reference":[{"key":"6615_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan AT, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380.","journal-title":"Lancet"},{"key":"6615_CR2","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","volume":"388","author":"L Zhang","year":"2016","unstructured":"Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016;388:1883\u201392.","journal-title":"Lancet"},{"key":"6615_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","volume":"18","author":"DG Pfister","year":"2020","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:873\u201398.","journal-title":"J Natl Compr Canc Netw"},{"key":"6615_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00280-007-0441-8","volume":"61","author":"L Zhang","year":"2008","unstructured":"Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharm. 2008;61:33\u201338.","journal-title":"Cancer Chemother Pharm"},{"key":"6615_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/annonc\/mdf002","volume":"13","author":"KF Foo","year":"2002","unstructured":"Foo KF, Tan EH, Leong SS, Wee JT, Tan T, Fong KW, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002;13:150\u20136.","journal-title":"Ann Oncol"},{"key":"6615_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140\u201356.","journal-title":"Nat Rev Drug Discov"},{"key":"6615_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1204-7","volume":"9","author":"JF Zhu","year":"2018","unstructured":"Zhu JF, Huang W, Yi HM, Xiao T, Li JY, Feng J, et al. Annexin A1-suppressed autophagy promotes nasopharyngeal carcinoma cell invasion and metastasis by PI3K\/AKT signaling activation. Cell Death Dis. 2018;9:1154.","journal-title":"Cell Death Dis"},{"key":"6615_CR8","doi-asserted-by":"publisher","first-page":"10186","DOI":"10.1002\/jcb.28303","volume":"120","author":"JH Yu","year":"2019","unstructured":"Yu JH, Chen L, Yu JY, Luo HQ, Wang L. PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis. J Cell Biochem. 2019;120:10186\u201394.","journal-title":"J Cell Biochem"},{"key":"6615_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-30","volume":"8","author":"J Chen","year":"2010","unstructured":"Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, et al. Epstein-Barr virus-encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med. 2010;8:30.","journal-title":"J Transl Med"},{"key":"6615_CR10","doi-asserted-by":"publisher","first-page":"e106098","DOI":"10.1371\/journal.pone.0106098","volume":"9","author":"W Wang","year":"2014","unstructured":"Wang W, Wen Q, Xu L, Xie G, Li J, Luo J, et al. Activation of Akt\/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma. PLoS One. 2014;9:e106098.","journal-title":"PLoS One"},{"key":"6615_CR11","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Lepp\u00e4 S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898\u2013905.","journal-title":"J Clin Oncol"},{"key":"6615_CR12","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, De Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl J Med. 2014;370:1008\u201318.","journal-title":"N. Engl J Med"},{"key":"6615_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl J Med. 2011;364:514\u201323.","journal-title":"N. Engl J Med"},{"key":"6615_CR14","doi-asserted-by":"publisher","first-page":"196ra199","DOI":"10.1126\/scitranslmed.3005747","volume":"5","author":"M Elkabets","year":"2013","unstructured":"Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al. mTORC1 inhibition is required for sensitivity to PI3K p110\u03b1 inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med. 2013;5:196ra199\u2013196ra199.","journal-title":"Sci Transl Med"},{"key":"6615_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol cell Biol. 2011;12:21\u201335.","journal-title":"Nat Rev Mol cell Biol"},{"key":"6615_CR16","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500\u20138.","journal-title":"Cancer Res"},{"key":"6615_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","volume":"1784","author":"R Marone","year":"2008","unstructured":"Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase\u2014moving towards therapy. Biochimica et Biophysica Acta (BBA)-Proteins Proteom. 2008;1784:159\u201385.","journal-title":"Biochimica et Biophysica Acta (BBA)-Proteins Proteom"},{"key":"6615_CR18","doi-asserted-by":"publisher","first-page":"e59879","DOI":"10.1371\/journal.pone.0059879","volume":"8","author":"F Yang","year":"2013","unstructured":"Yang F, Qian X-J, Qin W, Deng R, Wu X-Q, Qin J, et al. Dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLoS One. 2013;8:e59879.","journal-title":"PLoS One"},{"key":"6615_CR19","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10637-013-0007-z","volume":"31","author":"CH Wong","year":"2013","unstructured":"Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB, et al. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. Investig N. drugs. 2013;31:1399\u2013408.","journal-title":"Investig N. drugs"},{"key":"6615_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1158\/1535-7163.MCT-14-0548","volume":"14","author":"T Liu","year":"2015","unstructured":"Liu T, Sun Q, Li Q, Yang H, Zhang Y, Wang R, et al. Dual PI3K\/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma. Mol Cancer Therapeutics. 2015;14:429\u201339.","journal-title":"Mol Cancer Therapeutics"},{"key":"6615_CR21","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","volume":"60","author":"F Beaufils","year":"2017","unstructured":"Beaufils F, Cmiljanovic N, Cmiljanovic V, Bohnacker T, Melone A, Marone R, et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K\/mTOR Inhibitor as Clinical Candidate in Oncology. J Med Chem. 2017;60:7524\u201338.","journal-title":"J Med Chem"},{"key":"6615_CR22","first-page":"773","volume":"43","author":"K Yang","year":"2020","unstructured":"Yang K, Tang XJ, Xu FF, Liu JH, Tan YQ, Gao L, et al. PI3K\/mTORC1\/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells. Oncol Rep. 2020;43:773\u201382.","journal-title":"Oncol Rep"},{"key":"6615_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejca.2018.03.012","volume":"96","author":"A Wicki","year":"2018","unstructured":"Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, et al. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13). Eur J Cancer. 2018;96:6\u201316.","journal-title":"Eur J Cancer"},{"key":"6615_CR24","doi-asserted-by":"publisher","first-page":"e656","DOI":"10.1097\/HS9.0000000000000656","volume":"5","author":"GP Collins","year":"2021","unstructured":"Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, et al. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1\/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma. Hemasphere. 2021;5:e656.","journal-title":"Hemasphere"},{"key":"6615_CR25","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molmed.2018.08.003","volume":"24","author":"RR Madsen","year":"2018","unstructured":"Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-Associated PIK3CA Mutations in Overgrowth Disorders. Trends Mol Med. 2018;24:856\u201370.","journal-title":"Trends Mol Med"},{"key":"6615_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10717-z","volume":"7","author":"S Mjos","year":"2017","unstructured":"Mjos S, Werner HMJ, Birkeland E, Holst F, Berg A, Halle MK, et al. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Sci Rep. 2017;7:10240.","journal-title":"Sci Rep"},{"key":"6615_CR27","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.","journal-title":"Science"},{"key":"6615_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10020-022-00479-4","volume":"28","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Li P, Zhang X, Xu J, Xu J, Yu S, et al. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes. Mol Med. 2022;28:55.","journal-title":"Mol Med"},{"key":"6615_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.21037\/atm-21-698","volume":"9","author":"H Hu","year":"2021","unstructured":"Hu H, Zhu J, Zhong Y, Geng R, Ji Y, Guan Q, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K\/AKT\/mTOR signaling pathway. Ann Transl Med. 2021;9:410.","journal-title":"Ann Transl Med"},{"key":"6615_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1112-1","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, et al. The PI3K subunits, P110\u03b1 and P110\u03b2 are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020;19:10.","journal-title":"Mol Cancer"},{"key":"6615_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8:627\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"6615_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02162-w","volume":"21","author":"F Luo","year":"2021","unstructured":"Luo F, Cao J, Lu F, Zeng K, Ma W, Huang Y, et al. Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. Cancer Cell Int. 2021;21:458.","journal-title":"Cancer Cell Int"},{"key":"6615_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WNR.0b013e32801299cc","volume":"18","author":"SW Kim","year":"2007","unstructured":"Kim SW, Kim JB, Kim JH, Lee JK. Interferon-gamma-induced expressions of heat shock protein 60 and heat shock protein 10 in C6 astroglioma cells: identification of the signal transducers and activators of transcription 3-binding site in bidirectional promoter. Neuroreport. 2007;18:385\u20139.","journal-title":"Neuroreport"},{"key":"6615_CR34","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1172\/JCI67615","volume":"123","author":"A Kleinridders","year":"2013","unstructured":"Kleinridders A, Lauritzen HP, Ussar S, Christensen JH, Mori MA, Bross P, et al. Leptin regulation of Hsp60 impacts hypothalamic insulin signaling. J Clin Investig. 2013;123:4667\u201380.","journal-title":"J Clin Investig"},{"key":"6615_CR35","doi-asserted-by":"publisher","first-page":"e149906","DOI":"10.1172\/JCI149906","volume":"132","author":"R Kumar","year":"2022","unstructured":"Kumar R, Chaudhary AK, Woytash J, Inigo JR, Gokhale AA, Bshara W, et al. A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60. J Clin Invest. 2022;132:e149906.","journal-title":"J Clin Invest"},{"key":"6615_CR36","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1158\/0008-5472.CAN-04-0538","volume":"64","author":"JA Morrison","year":"2004","unstructured":"Morrison JA, Gulley ML, Pathmanathan R, Raab-Traub N. Differential Signaling Pathways Are Activated in the Epstein-Barr Virus-Associated Malignancies Nasopharyngeal Carcinoma and Hodgkin Lymphoma. Cancer Res. 2004;64:5251\u201360.","journal-title":"Cancer Res"},{"key":"6615_CR37","first-page":"319","volume":"19","author":"WK Yip","year":"2008","unstructured":"Yip WK, Leong VCS, Abdullah MA, Yusoff S, Seow HF. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep. 2008;19:319\u201328.","journal-title":"Oncol Rep"},{"key":"6615_CR38","first-page":"467","volume":"20","author":"AB-Y Hui","year":"2002","unstructured":"Hui AB-Y, Lo K-W, Teo PM, To K-F, Huang DP. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol. 2002;20:467\u201373.","journal-title":"Int J Oncol"},{"key":"6615_CR39","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ng.3006","volume":"46","author":"D-C Lin","year":"2014","unstructured":"Lin D-C, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46:866\u201371.","journal-title":"Nat Genet"},{"key":"6615_CR40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ijc.21444","volume":"118","author":"YY Or","year":"2006","unstructured":"Or YY, Hui AB, To KF, Lam CN, Lo KW. PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer. 2006;118:1065\u20137.","journal-title":"Int J Cancer"},{"key":"6615_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/07853890.2014.912836","volume":"46","author":"M Martini","year":"2014","unstructured":"Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K\/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46:372\u201383.","journal-title":"Ann Med"},{"key":"6615_CR42","doi-asserted-by":"publisher","first-page":"10186","DOI":"10.1002\/jcb.28303","volume":"120","author":"JH Yu","year":"2019","unstructured":"Yu JH, Chen L, Yu JY, Luo HQ, Wang L. PI3K\u2010PKB\u2010mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis. J Cell Biochem. 2019;120:10186\u201394.","journal-title":"J Cell Biochem"},{"key":"6615_CR43","doi-asserted-by":"publisher","first-page":"12813","DOI":"10.3390\/ijms222312813","volume":"22","author":"B Zhang","year":"2021","unstructured":"Zhang B, Luk C, Valadares J, Aronis C, Foukas LC. Dominant Role of PI3K p110\u03b1 over p110\u03b2 in Insulin and \u03b2-Adrenergic Receptor Signalling. Int J Mol Sci. 2021;22:12813.","journal-title":"Int J Mol Sci"},{"key":"6615_CR44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","volume":"17","author":"R Katso","year":"2001","unstructured":"Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615\u201375.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"6615_CR45","first-page":"707","volume":"1","author":"AS Clark","year":"2002","unstructured":"Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol cancer Therapeutics. 2002;1:707\u201317.","journal-title":"Mol cancer Therapeutics"},{"key":"6615_CR46","first-page":"1087","volume":"62","author":"L Hu","year":"2002","unstructured":"Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3\u2032-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62:1087\u201392.","journal-title":"Cancer Res"},{"key":"6615_CR47","first-page":"3986","volume":"61","author":"J Brognard","year":"2001","unstructured":"Brognard J, Clark AS, Ni Y, Dennis PA. Akt\/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61:3986\u201397.","journal-title":"Cancer Res"},{"key":"6615_CR48","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.18632\/aging.202488","volume":"13","author":"J Ye","year":"2021","unstructured":"Ye J, Qi L, Du Z, Yu L, Chen K, Li R, et al. Calreticulin: a potential diagnostic and therapeutic biomarker in gallbladder cancer. Aging (Albany NY). 2021;13:5607\u201320.","journal-title":"Aging (Albany NY)"},{"key":"6615_CR49","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s10565-022-09736-y","volume":"39","author":"Y Guo","year":"2023","unstructured":"Guo Y, Wu H, Xiong J, Gou S, Cui J, Peng T. miR-222-3p-containing macrophage-derived extracellular vesicles confer gemcitabine resistance via TSC1-mediated mTOR\/AKT\/PI3K pathway in pancreatic cancer. Cell Biol Toxicol. 2023;39:1203\u201314.","journal-title":"Cell Biol Toxicol"},{"key":"6615_CR50","first-page":"8295","volume":"7","author":"F Wen","year":"2014","unstructured":"Wen F, He S, Sun C, Li T, Wu S. PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. Int J Clin Exp Pathol. 2014;7:8295.","journal-title":"Int J Clin Exp Pathol"},{"key":"6615_CR51","first-page":"1554","volume":"11","author":"JS Lee","year":"2018","unstructured":"Lee JS, Lee HW, Lee EH, Park MI, Lee JS, Kim MS, et al. Prognostic significance of phosphoinositide 3-kinase p110\u03b1 and p110\u03b2 isoforms in non-small cell lung cancer. Int J Clin Exp Pathol. 2018;11:1554\u201361.","journal-title":"Int J Clin Exp Pathol"},{"key":"6615_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/PAI.0000000000000524","volume":"26","author":"K Kim","year":"2018","unstructured":"Kim K, Lee HW. Expression of Phosphoinositide 3-Kinase p110\u03b1 and p110\u03b2 Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma. Appl Immunohistochem Mol Morphol. 2018;26:740\u20138.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"6615_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","volume":"24","author":"C Tarantelli","year":"2018","unstructured":"Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, et al. PQR309 Is a Novel Dual PI3K\/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. Clin Cancer Res. 2018;24:120\u20139.","journal-title":"Clin Cancer Res"},{"key":"6615_CR54","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.3324\/haematol.2018.207027","volume":"104","author":"L Aresu","year":"2019","unstructured":"Aresu L, Ferraresso S, Marconato L, Cascione L, Napoli S, Gaudio E, et al. New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. Haematologica. 2019;104:e256\u2013e259.","journal-title":"Haematologica"},{"key":"6615_CR55","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.3390\/cells10112916","volume":"10","author":"IL Hsin","year":"2021","unstructured":"Hsin IL, Shen HP, Chang HY, Ko JL, Wang PH. Suppression of PI3K\/Akt\/mTOR\/c-Myc\/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K\/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines. Cells. 2021;10:2916.","journal-title":"Cells"},{"key":"6615_CR56","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/jcb.23405","volume":"113","author":"N Awasthi","year":"2012","unstructured":"Awasthi N, Yen PL, Schwarz MA, Schwarz RE. The efficacy of a novel, dual PI3K\/mTOR inhibitor NVP\u2010BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem. 2012;113:784\u201391.","journal-title":"J Cell Biochem"},{"key":"6615_CR57","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.bbrc.2020.06.011","volume":"529","author":"DK Jang","year":"2020","unstructured":"Jang DK, Lee YG, Chae YC, Lee JK, Paik WH, Lee SH, et al. GDC-0980 (apitolisib) treatment with gemcitabine and\/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K\/Akt\/mTOR pathway. Biochem Biophys Res Commun. 2020;529:1242\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"6615_CR58","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.gastro.2016.03.010","volume":"151","author":"SM W\u00f6rmann","year":"2016","unstructured":"W\u00f6rmann SM, Song L, Ai J, Diakopoulos KN, Kurkowski MU, G\u00f6rg\u00fcl\u00fc K, et al. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. Gastroenterology. 2016;151:180\u2013.e112.","journal-title":"Gastroenterology"},{"key":"6615_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.172","volume":"6","author":"T Namba","year":"2015","unstructured":"Namba T, Kodama R, Moritomo S, Hoshino T, Mizushima T. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3\u03b2-Snail pathway. Cell Death Dis. 2015;6:e1795.","journal-title":"Cell Death Dis"},{"key":"6615_CR60","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1053\/j.gastro.2015.07.058","volume":"149","author":"NS Nagathihalli","year":"2015","unstructured":"Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, et al. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Gastroenterology. 2015;149:1932\u2013.e1939.","journal-title":"Gastroenterology"},{"key":"6615_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semcancer.2019.09.022","volume":"68","author":"PS Thilakasiri","year":"2021","unstructured":"Thilakasiri PS, Dmello RS, Nero TL, Parker MW, Ernst M, Chand AL. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Semin Cancer Biol. 2021;68:31\u201346.","journal-title":"Semin Cancer Biol"},{"key":"6615_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pharmthera.2015.10.004","volume":"162","author":"EZ Chai","year":"2016","unstructured":"Chai EZ, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharm Ther. 2016;162:86\u201397.","journal-title":"Pharm Ther"},{"key":"6615_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03844-z","volume":"12","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma L, Sun Y, Yu W, Wang X. Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer. Cell Death Dis. 2021;12:561.","journal-title":"Cell Death Dis"},{"key":"6615_CR64","doi-asserted-by":"publisher","first-page":"e0237943","DOI":"10.1371\/journal.pone.0237943","volume":"15","author":"Y Pan","year":"2020","unstructured":"Pan Y, Zhou F, Zhang R, Claret FX. Correction: Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLoS One. 2020;15:e0237943.","journal-title":"PLoS One"},{"key":"6615_CR65","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.CD-11-0218","volume":"1","author":"PK Vogt","year":"2011","unstructured":"Vogt PK, Hart JR. PI3K and STAT3: a new alliance. Cancer Discov. 2011;1:481\u20136.","journal-title":"Cancer Discov"},{"key":"6615_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00292-w","volume":"10","author":"J Wang","year":"2021","unstructured":"Wang J, Lv X, Guo X, Dong Y, Peng P, Huang F, et al. Feedback activation of STAT3 limits the response to PI3K\/AKT\/mTOR inhibitors in PTEN-deficient cancer cells. Oncogenesis. 2021;10:8.","journal-title":"Oncogenesis"},{"key":"6615_CR67","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207\u201321.","journal-title":"Cancer Cell"},{"key":"6615_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01327-4","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Diao B, Guo S, Huang X, Yang C, Feng Z, et al. VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism. Nat Commun. 2017;8:1322.","journal-title":"Nat Commun"},{"key":"6615_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/1878-0261.12053","volume":"11","author":"VF Merino","year":"2017","unstructured":"Merino VF, Cho S, Liang X, Park S, Jin K, Chen Q, et al. Inhibitors of STAT3, \u03b2-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors. Mol Oncol. 2017;11:552\u201366.","journal-title":"Mol Oncol"},{"key":"6615_CR70","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/CBM-200410","volume":"30","author":"Y Tang","year":"2021","unstructured":"Tang Y, Yang Y, Luo J, Liu S, Zhan Y, Zang H, et al. Overexpression of HSP10 correlates with HSP60 and Mcl-1 levels and predicts poor prognosis in non-small cell lung cancer patients. Cancer Biomark. 2021;30:85\u201394.","journal-title":"Cancer Biomark"},{"key":"6615_CR71","doi-asserted-by":"publisher","first-page":"801","DOI":"10.4161\/cbt.7.6.6281","volume":"7","author":"F Cappello","year":"2008","unstructured":"Cappello F, Conway de Macario E, Maras\u00e0 L, Zummo G, Macario AJ. Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biol Ther. 2008;7:801\u20139.","journal-title":"Cancer Biol Ther"},{"key":"6615_CR72","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/carcin\/bgp087","volume":"30","author":"YP Tsai","year":"2009","unstructured":"Tsai YP, Yang MH, Huang CH, Chang SY, Chen PM, Liu CJ, et al. Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis. 2009;30:1049\u201357.","journal-title":"Carcinogenesis"},{"key":"6615_CR73","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0304-3835(97)00255-3","volume":"119","author":"M Abu-Hadid","year":"1997","unstructured":"Abu-Hadid M, Wilkes JD, Elakawi Z, Pendyala L, Perez RP. Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines. Cancer Lett. 1997;119:63\u201370.","journal-title":"Cancer Lett"},{"key":"6615_CR74","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/1061186X.2021.1920025","volume":"30","author":"B Sun","year":"2022","unstructured":"Sun B, Li G, Yu Q, Liu D, Tang X. HSP60 in cancer: a promising biomarker for diagnosis and a potentially useful target for treatment. J Drug Target. 2022;30:31\u201345.","journal-title":"J Drug Target"},{"key":"6615_CR75","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF00686173","volume":"32","author":"E Kimura","year":"1993","unstructured":"Kimura E, Enns RE, Thiebaut F, Howell SB. Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line. Cancer Chemother Pharm. 1993;32:279\u201385.","journal-title":"Cancer Chemother Pharm"},{"key":"6615_CR76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00428-014-1588-4","volume":"465","author":"O Tapia","year":"2014","unstructured":"Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, et al. The PI3K\/AKT\/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 2014;465:25\u201333.","journal-title":"Virchows Arch"},{"key":"6615_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128\u201334.","journal-title":"Nat Rev Cancer"},{"key":"6615_CR78","doi-asserted-by":"publisher","first-page":"e0153075","DOI":"10.1371\/journal.pone.0153075","volume":"11","author":"SA Park","year":"2016","unstructured":"Park SA, Lee JW, Herbst RS, Koo JS. GSK-3\u03b1 Is a Novel Target of CREB and CREB-GSK-3\u03b1 Signaling Participates in Cell Viability in Lung Cancer. PLoS One. 2016;11:e0153075.","journal-title":"PLoS One"},{"key":"6615_CR79","doi-asserted-by":"publisher","first-page":"20380","DOI":"10.18632\/aging.103829","volume":"12","author":"XZ Yang","year":"2020","unstructured":"Yang XZ, Chen XM, Zeng LS, Deng J, Ma L, Jin C, et al. Rab1A promotes cancer metastasis and radioresistance through activating GSK-3\u03b2\/Wnt\/\u03b2-catenin signaling in nasopharyngeal carcinoma. Aging (Albany NY). 2020;12:20380\u201395.","journal-title":"Aging (Albany NY)"},{"key":"6615_CR80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11060-010-0491-3","volume":"104","author":"A Dickey","year":"2011","unstructured":"Dickey A, Schleicher S, Leahy K, Hu R, Hallahan D, Thotala DK. GSK-3\u03b2 inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J Neurooncol. 2011;104:145\u201353.","journal-title":"J Neurooncol"},{"key":"6615_CR81","doi-asserted-by":"publisher","first-page":"8986","DOI":"10.18632\/oncotarget.1510","volume":"5","author":"J Kroon","year":"2014","unstructured":"Kroon J, in \u2018t Veld LS, Buijs JT, Cheung H, van der Horst G, van der Pluijm G. Glycogen synthase kinase-3\u03b2 inhibition depletes the population of prostate cancer stem\/progenitor-like cells and attenuates metastatic growth. Oncotarget. 2014;5:8986\u201394.","journal-title":"Oncotarget"},{"key":"6615_CR82","doi-asserted-by":"publisher","first-page":"e91231","DOI":"10.1371\/journal.pone.0091231","volume":"9","author":"J Zeng","year":"2014","unstructured":"Zeng J, Liu D, Qiu Z, Huang Y, Chen B, Wang L, et al. GSK3\u03b2 overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS One. 2014;9:e91231.","journal-title":"PLoS One"},{"key":"6615_CR83","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/mc.23090","volume":"58","author":"M El Amrani","year":"2019","unstructured":"El Amrani M, Corfiotti F, Corvaisier M, Vasseur R, Fulbert M, Skrzypczyk C, et al. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Mol Carcinog. 2019;58:1985\u201397.","journal-title":"Mol Carcinog"},{"key":"6615_CR84","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-08-4312","volume":"69","author":"Z Wang","year":"2009","unstructured":"Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69:2400\u20137.","journal-title":"Cancer Res"},{"key":"6615_CR85","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/jnc.14899","volume":"153","author":"C von Achenbach","year":"2020","unstructured":"von Achenbach C, Weller M, Kaulich K, Gramatzki D, Zacher A, Fabbro D, et al. Synergistic growth inhibition mediated by dual PI3K\/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. J Neurochem. 2020;153:510\u201324.","journal-title":"J Neurochem"},{"key":"6615_CR86","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06615-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T11:02:02Z","timestamp":1711796522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06615-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,30]]},"references-count":86,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["6615"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06615-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,30]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethical Review Committee of Sun Yat-sen University Cancer Center (B2020-394-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"237"}}